BRAF and melanoma: Gowda et al30 assessed the nanoliposomal delivery of A2 inhibitor arachidonyl trimethyl ketone in melanoma treatment by using normal human fibroblast cell lines FF2441, BRAF melanoma cell lines, and random human melanoma specimens.